Beverly Hills Private Wealth LLC Buys 14,288 Shares of GSK plc (NYSE:GSK)

Beverly Hills Private Wealth LLC raised its position in shares of GSK plc (NYSE:GSK - Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,397 shares of the pharmaceutical company's stock after acquiring an additional 14,288 shares during the period. Beverly Hills Private Wealth LLC's holdings in GSK were worth $994,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC boosted its position in shares of GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after buying an additional 278 shares during the period. GC Wealth Management RIA LLC lifted its position in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after acquiring an additional 353 shares in the last quarter. Jacobi Capital Management LLC boosted its holdings in GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after acquiring an additional 389 shares during the period. Gladstone Institutional Advisory LLC grew its position in GSK by 3.4% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after acquiring an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co raised its stake in shares of GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock valued at $262,000 after purchasing an additional 414 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Down 0.7 %

Shares of GSK traded down $0.24 during trading hours on Friday, reaching $36.63. The company's stock had a trading volume of 3,511,468 shares, compared to its average volume of 4,786,523. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $75.58 billion, a price-to-earnings ratio of 23.04, a P/E/G ratio of 1.12 and a beta of 0.51. The company has a 50 day moving average of $37.65 and a two-hundred day moving average of $35.99. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 EPS. As a group, research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.60%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 86.60%.

Analyst Ratings Changes

GSK has been the subject of several analyst reports. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. BNP Paribas started coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.